ArticleScientifica2026
Chemopreventive Effects of Lycopene in miR-21 Knockout and Wild-Type Pancreatic Cancer Cells.
Article in Scientifica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is one of the most lethal malignancies, characterized by late diagnosis, rapid progression, and resistance to conventional therapies. The oncogenic microRNA miR-21 is frequently upregulated in pancreatic tumors and contributes to tumor growth, migration, and chemoresistance by targeting tumor suppressor genes. Lycopene, a naturally occurring carotenoid with antioxidant and anti-inflammatory properties, has shown promise as a chemopreventive agent in several cancer types. This study investigates the therapeutic potential of lycopene in human pancreatic cancer cell lines (PANC-1 and MIA PaCa-2) and their miR-21 knockout counterparts. Treatment with 50 μM lycopene significantly reduced cell viability, colony formation, migration, and spheroid integrity and decreased intracellular reactive oxygen species (ROS) levels, with more pronounced effects in miR-21-deficient cells. These findings highlight the role of miR-21 in modulating lycopene sensitivity and support the potential of lycopene as an adjunctive therapeutic agent in pancreatic cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.